Compare AstraZeneca plc (AZN) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs TotalEnergies SE — how do they compare? AstraZeneca plc trades at $168.46 (market cap $253.13B), while TotalEnergies SE trades at $81.18 (market cap $180.15B). The key difference: AstraZeneca plc is the larger of the two by market cap, and TotalEnergies SE pays the higher dividend (5.21%). Which is the better fit depends on your goals.
| AZN | TTE | |
|---|---|---|
Market Cap | $253.13B | $180.15B |
Sector | Health | Energy |
52-Week High | $209.48 | $93.60 |
52-Week Low | $137.44 | $57.39 |
Enterprise Value | $279.37B | $214.29B |
Dividend Yield | 1.92% | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TotalEnergies (TTE) trades at $81.21, up 3.45% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $2.45, beating expectations, but revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation ratios are attractive with a P/E of 12.05 and EV/EBITDA of 4.93. Recent news highlights strategic moves in LNG and solar divestments to focus on larger renewable projects.
The outlook for TTE is supported by strong cash flow generation and a 'Buy' consensus from 57.6% of analysts, but risks include declining revenue trends, geopolitical exposure, and regulatory pressures. The stock offers value with solid profitability and shareholder returns via dividends, yet investors should weigh execution risks in its energy transition strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
